ArticleThe British journal of dermatology2021
Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways.
Article in The British journal of dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 50 citations in OpenAlex.
- Keratinocyte-specific STAT3 knockout attenuates imiquimod-induced psoriasiform phenotype in mice.Experimental animals · 2026Article
- Mechanisms of pruritus and advances in traditional Chinese medicine therapy (Review).Molecular medicine reports · 2026Review
- Efficacy of upadacitinib in palmoplantar pustulosis case series highlights the complex immune response patterns.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- PRELP negatively regulates IL-17A-mediated proliferation and the inflammatory response in psoriasis.Signal transduction and targeted therapy · 2026Article
- Emerging Targets in Psoriatic Arthritis: Dual IL-17A/F and Selective TYK2 Inhibition in a Clinical Perspective.Mediterranean journal of rheumatology · 2026Review
- Single-Cell RNA Sequencing Revealing Dysregulated Perturbations of Tregs in Psoriasis and Construction of a Treg-Related Diagnostic Model via a 101- Combination Machine Learning Computational FrameworkEndocrine, metabolic & immune disorders drug targets · 2026Article
- Targeting IL-17 Presents a Promising Strategy for Treating Diseases Related to the Dysregulation of Lipid Homeostasis.Mediators of inflammation · 2026Review
- Idiopathic granulomatous mastitis with GMENA syndrome: clinical features, glucocorticoid response, and prognosis - a 12-year retrospective cohort study from a single center.Frontiers in immunology · 2026Article
- Vunakizumab for IL-17A-Mediated Diseases: A Review in Psoriasis and Spondyloarthritis.Biologics : targets & therapy · 2026Review
- Shield microneedles loaded with biphasic-delivery liposomes modulate skin oxidation/immunity dual-axis for psoriasis therapy.Materials today. Bio · 2025Article
- IL-17C as a Driver of Inflammation in Psoriasis.Advances in therapy · 2025Review
- Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure.Dermatology and therapy · 2025Review
- Brodalumab: Seven-Year US Pharmacovigilance Report.Dermatology and therapy · 2025Article
- Macrophagic Ym1 orchestrates γδT cell-derived IL-17 production and keratinocyte functionality to mediate psoriasis-like skin inflammation.Communications biology · 2025Article
- An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis.Nature communications · 2025Article
- Galectin-9: diverse roles in skin disease.Frontiers in allergy · 2025Review
- Interventions in cytokine signaling: novel horizons for psoriasis treatment.Frontiers in immunology · 2025Review
- Brodalumab: Six-Year US Pharmacovigilance Report.Dermatology and therapy · 2025Article
- Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions.Immune network · 2024Review
- Gram-negative anaerobes elicit a robust keratinocytes immune response with potential insights into HS pathogenesis.Experimental dermatology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe interleukin (IL)-23/IL-17 immune axis is of central importance in psoriasis. However, the impact of IL-17 family cytokines other than IL-17A in psoriasis has not been fully established.
objectivesTo elucidate the contribution of IL-17 family cytokines in psoriasis.
methodsTo address the expression and localization of IL-17 family cytokines, lesional and nonlesional skin samples from patients with psoriasis were analysed by several complementary methods, including quantitative polymerase chain reaction, immunoassays, in situ hybridization and immunohistochemistry. Mechanistic studies assessing the functional activity of IL-17 family cytokines were performed using ex vivo cultured human skin biopsies and primary human keratinocytes.
resultsWe demonstrated that IL-17A, IL-17F, IL-17A/F and IL-17C are expressed at increased levels in psoriasis lesional skin and induce overlapping gene expression responses in ex vivo cultured human skin that correlate with the transcriptomic signature of psoriasis skin. Furthermore, we showed that brodalumab, in contrast to ixekizumab, normalizes gene expression responses induced by the combination of IL-17A, IL-17F, IL-17A/F and IL-17C in human keratinocytes.
conclusionsSeveral IL-17 ligands signalling through IL-17RA are overexpressed in psoriasis skin and induce similar psoriasis-related inflammatory pathways demonstrating their relevance in relation to therapeutic intervention in psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.